Tyme Technologies, Inc.

Cost-cutting has become the norm for biopharmaceutical companies in 2023 as drug developers struggle to raise capital for ongoing research and development programs, never mind bringing in new funding

Rivus Pharmaceuticals Inc. already had its lead Controlled Metabolic Accelerator (CMA), known as HU6, in a Phase IIa clinical trial last year when it raised $35m in series A venture capital. Now, wit

Syros Pharmaceuticals, Inc. significantly extended its financial runway through three concurrent transactions on 5 July that are expected to fund company operations into 2025 and get it well past the